Cart (0 Items)
Your cart is currently empty.
View Products
| Size | 100ug, 1MG |
|---|---|
| Brand | ProteoGenix |
| Product type | Recombinant Proteins |
| Expression system | XtenCHO |
| Applications | Elisa, WB |
| Product name | Asfotase alfa Biosimilar - Anti-TNSALP fusion protein - Research Grade |
|---|---|
| Species | Homo sapiens |
| Expression system | Eukaryotic expression |
| Purity | >90% by SDS-PAGE. |
| Buffer | 0.01M PBS, pH 7.4. |
| Delivery condition | Blue ice (+4°C) |
| Delivery lead time in business days | 3-5 days if in stock; 3-5 weeks if production needed |
| Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | 4°C for short term; -20°C for long term |
| Brand | ProteoGenix |
| Aliases /Synonyms | anti-TNSALP, Alkaline phosphatase liver/bone/kidney isozyme, AP-TNAP, Alkaline phosphatase, tissue-nonspecific isozyme, ALPL |
| Reference | PX-TA2032 |
| Note | For research use only. |
| Isotype | Fusion - [ALPL (alkaline phosphatase, TNSALP, tissue non-specific alkaline phosphatase) 18-502]2 - IGHG1 Fc (Fragment constant) - Asp-Ile-deca-aspartate |
Asfotase Alfa Biosimilar – Anti-TNSALP Fusion Protein
Asfotase alfa is a recombinant fusion protein designed to mimic the activity of tissue-nonspecific alkaline phosphatase (TNSALP), an enzyme involved in bone mineralization and phosphate metabolism. Reduced activity of TNSALP leads to accumulation of substrates such as inorganic pyrophosphate, which interferes with normal skeletal development.
This Asfotase alfa biosimilar is produced as a research-grade recombinant protein to support studies investigating alkaline phosphatase activity, metabolic bone disorders, and enzyme replacement strategies.
Tissue-nonspecific alkaline phosphatase plays a key role in regulating phosphate metabolism and mineral deposition in bone tissue. Deficiency of this enzyme is associated with hypophosphatasia, a rare metabolic disease characterized by impaired bone mineralization.
Because of its central role in phosphate metabolism, asfotase alfa has become an important research tool for scientists studying:
The therapeutic protein Strensiq® (asfotase alfa) is an enzyme replacement therapy used clinically for hypophosphatasia. Research-grade asfotase alfa biosimilars allow laboratories to investigate the biological activity of this enzyme and to explore the molecular pathways involved in TNSALP deficiency.
Studying Strensiq asfotase alfa analogs helps researchers understand enzyme replacement approaches and the biochemical mechanisms regulating mineralization.
This Asfotase alfa fusion protein can support multiple experimental approaches including:
ProteoGenix offers some of the most competitive Asfotase alfa prices on the market for research-grade proteins. Our Asfotase alfa biosimilar is produced under controlled conditions to ensure high quality, consistency, and reliable performance in experimental applications.
For detailed information regarding Asfotase alfa price or cost, researchers and laboratories can request a quotation from our scientific team.
Send us a message from the form below
Reviews
There are no reviews yet.